🇺🇸 Plasma-derived FVIII/VWF concentrate in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Haemorrhage — 2 reports (16.67%)
  2. Pulmonary Embolism — 2 reports (16.67%)
  3. Cardiomegaly — 1 report (8.33%)
  4. Device Related Infection — 1 report (8.33%)
  5. Drug Intolerance — 1 report (8.33%)
  6. Factor Viii Inhibition — 1 report (8.33%)
  7. Infection — 1 report (8.33%)
  8. Pneumonia — 1 report (8.33%)
  9. Pneumothorax — 1 report (8.33%)
  10. Right Ventricular Failure — 1 report (8.33%)

Source database →

Other Hematology approved in United States

Frequently asked questions

Is Plasma-derived FVIII/VWF concentrate approved in United States?

Plasma-derived FVIII/VWF concentrate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Plasma-derived FVIII/VWF concentrate in United States?

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the originator. The local marketing authorisation holder may differ — check the official source linked above.